A new modified sunitinib schedule for metastatic renal cell cancer (mRCC): A pilot study
2012-01-01 Buti, S; Donini, M; Lazzarelli, S; Brighenti, M; Passalacqua, R
Safety and efficacy of Cabozantinib for metastatic renal cell carcinoma (mRCC): real world data from an Italian Expanded Access Program (EAP)
2017-01-01 Procopio, G; Prisciandaro, M; Iacovelli, R; Mancini, M; Fornarini, G; Facchini, G; Carteni, G; Napolitano, M; Sternberg, Cn; Caserta, C; Bregni, M; Massari, F; Buti, S; Biasco, E; De Giorgi, U; Zustovich, F; Ratta, R; Ortega, C; Tortora, G; Verzoni, E
Dose-dense chemotherapy with modified TCF regimen (TCF-DD) in metastatic gastric cancer (MGC): A feasibility study
2006-01-01 Dalla Chiesa, M; Tomasello, G; Buti, S; Negri, F; Buononato, M; Lazzarelli, S; Brighenti, M; Donati, G; Cattaneo, M; Passalacqua, R
Gefitinib plus interleukin-2 (IL-2) in previously treated patients with advanced non-small-cell lung cancer (NSCLC)
2005-01-01 Buti, S; Chiesa, Md; Tomasello, G; Negri, F; Machiavelli, A; Bosio, G; Stifani, I; Betti, M; Buononato, M; Passalacqua, R
LOH as “the missing instability” potentially underlying the tumor immunogenicity: on the trails of a correlation between fractional allelic loss and response to nivolumab in renal cancer
2017-01-01 Bersanelli, M; Gnetti, L; Azzoni, C; Bottarelli, L; Gasparro, D; Leonardi, F; Silini, Em; Buti, S
Complete remission (CR) during treatment for metastatic renal cell carcinoma (mRCC) with tyrosine kinase inhibitors (TKIs)
2015-01-01 Santini, D; Santoni, M; Conti, A; Procopio, G; Verzoni, E; Galli, L; Di Lorenzo, G; De Giorgi, U; De Lisi, D; Nicodemo, M; Maruzzo, M; Massari, F; Buti, S; Biasco, E; Ricotta, R; Porta, C; Vincenzi, B; Marchetti, P; Cascinu, S; Tonini, G
Adjuvant low-dose interleukin-2 (IL2) plus interferone-alpha (IFN) in operable renal cell cancer (RCC). A phase III, randomized, multicenter, independent trial of the Italian Oncology Group for Clinical Research (GOIRC)
2007-01-01 Passalacqua, R; Buzio, C; Buti, S; Labianca, R; Porta, C; Boni, C; Rondini, E; Camisa, R; Sabbatini, R; Artioli, F; Caminiti, C
Relationship between enzalutamide activity and previous antiandrogen withdrawal syndrome (AWS) in patients with metastatic castration-resistant prostate cancer (MCRPC)
2015-01-01 Alesini, D; Sisani, M; Altavilla, A; Procopio, G; Hamzaj, A; Grillone, F; Massari, F; Marrocolo, F; Zaniboni, A; Mattioli, R; Buti, S; Battaglia, M; Caffo, O; De Angelis, V; Bracarda, S
Influenza vaccine indication during anticancer therapy with immune-checkpoint inhibitors: A transversal challenge for patient's counselling preliminary analysis of the INVIDIa study
2017-01-01 Bersanelli, M; Castrignanò, P; Gambale, E; Cortellini, A; Tiseo, M; Natoli, C; Ficorella, C; Panni, S; Rossetti, S; Papa, A; Mazzoni, F; Facchini, G; De Giorgi, U; Procopio, G; Atzori, F; Sava, T; De Luca, E; Maestri, A; Massari, F; Buti, S
Negative prognostic factors and resulting clinical outcome in patients (pts) with metastatic renal cell carcinoma (mRCC) included in the Italian nivolumab expanded access program (EAP)
2017-01-01 Bracarda, S; Galli, L; Maruzzo, M; Lo Re, G; Buti, S; Favaretto, A; Costanzo, Fd; Sacco, C; Merlano, M; Mucciarini, C; Zafarana, E; Romito, S; Maestri, A; Giorgio, Cg; Ionta, Mt; Turci, D; De Giorgi, U; Procopio, G; Cortesi, E; Porta, C
Final results of a dose-finding phase II trial with a triple combination therapy in metastatic renal cell cancer (MRCC): Bevacizumab (B) plus Immunotherapy (I) plus Chemotherapy (C) (BIC). Antitumor effects and variations of circulating T-regulatory cells (Treg) and other T lymphocytes subsets
2009-01-01 Passalacqua, R; Buti, S; Brighenti, M; Rivoltini, L; Castelli, C; Camisaschi, C; Simonelli, C; Lo Re, G; Mattioli, R; Mazza, G; Dalla Chiesa, M; Tomasello, G; Negri, F; Lazzarelli, S
Clinical outcomes and toxicity of estramustine phosphate (EP) addition to docetaxel (D) as first-line therapy for castration-resistant prostate cancer (CRPC): A cumulative analysis on 243 patients (pts) from two randomized phase II trials
2013-01-01 Caffo, O; Sava, T; Zustovich, F; Lodde, M; Sacco, C; Lo Re, G; Buti, S; Basso, U; Gamucci, T; Facchini, G; Perin, A; Segati, R; Russo, L; Veccia, A; Galligioni, E
Bevacizumab (B) plus low-doses immunotherapy (IT) plus chemotherapy (CT) (BIC) in metastatic renal cell cancer (mRCC): Antitumor effects and variations of T-regulatory cells (Treg) and other T lymphocytes subsets. A study of the Italian Oncology Group for Clinical Research (GOIRC)
2008-01-01 Passalacqua, R; Buti, S; Rivoltini, L; Castelli, C; Camisaschi, C; Simonelli, C; Lo Re, G; Mattioli, R; Mazza, G; Brighenti, M; Lazzarelli, S
Potential role of hypovitaminosis D in renal cell carcinoma patients treated with immune-checkpoint inhibitors
2017-01-01 Bersanelli, M; Vaglio, A; Sverzellati, N; Galetti, M; Incerti, M; Parziale, R; Corrado, M; Cosenza, A; Ferri, L; Leonardi, F; Buti, S
Dose-dense chemotherapy with Docetaxel, Cisplatin, folinic acid and 5-fluorouracil (TCAF DD) in metastatic gastric cancer (MGC): A feasibility study
2006-01-01 Dalla Chiesa, M; Tomasello, G; Buti, S; Negli, F; Buononato, M; Lazzarelli, S; Brighenti, M; Passalacqua, R
Phase III, randomised, multicentre, controlled trial of maintenance biotherapy for metastatic renal cell cancer with Interleukin-2 and Interferon-alpha-2a. A study of the Italian Oncological Group for Clinical Research (GOIRC)
2004-01-01 Passalacqua, R; Buzio, C; Porta, C; Labianca, R; Frassoldati, A; Buti, S; Pezzuolo, D; Vaglio, A; Tomasello, Gl; Dalla Chiesa, M; Camisa, R; Caminiti, C
Primo caso di carcinoma vescicale sarcomatoide associato a BKV in paziente trapiantato di rene: possibile ruolo dell’immunoistochimica per BKV-TAg e p16 su citologia urinaria nella diagnosi precoce di neoplasia
2015-01-01 Gandolfini, I; Piotti, G; Pilato, Fp; Buti, S; Bersanelli, M; Ferretti, S; Nizzoli, C; Galetti, M; Gnetti, L; Palmisano, A; Cremaschi, E; Delsante, M; Rocco, R; David, S; Maggiore, U
Sopravvivenza e risposta alla terapia in 139 pazienti affetti da Carcinoma Renale Metastatico (CRm) trattati con Interleukina-2 (IL-2) ed Interferone Alfa (IFNα) a basse dosi. Influenza del rischio prognostico rilevato alla diagnosi
2006-01-01 Vaglio, A; Bongiovanni, C; Alberici, F; Manna, C; Passalacqua, R; Buti, S; David, S; Buzio, C
Gefitinib (G) plus Interleukin-2 (IL-2) in previously treated patients with advanced non-small-cell lung cancer (NSCLC)
2007-01-01 Tomasello, G; Buti, S; Bosio, G; Stifani, I; Maestrelli, M; Brighenti, M; Porzio, R; Lazzarelli, S; Negri, F; Longarini, R; Passalacqua, R
Phase III, randomized, multicentre trial of maintenance biotherapy with interleukin-2 (IL-2) and interferon-alpha (IFN) for metastatic renal cell cancer (RCC)
2005-01-01 Passalacqua, R; Buzio, C; Dalla Chiesa, M; Camisa, R; Porta, C; Labianca, R; Frassoldati, A; Buti, S; Pezzuolo, D; Tomasello, G; Caminiti, C
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile
Scopri
Tipologia
- 1 Articolo su rivista1657
Data di pubblicazione
- 2020 - 2024117
- 2010 - 2019802
- 2000 - 2009512
- 1990 - 1999174
- 1980 - 198951
- 1979 - 19791
Editore
- ASCO pubs11
- ELSEVIER9
- Elsevier7
- SAGE PUBLICATIONS LTD5
- Edra3
- INT UNION CRYSTALLOGRAPHY3
- LIPPINCOTT WILLIAMS & WILKINS3
- SPRINGERNATURE3
- WILEY3
- BioMed Central2
Rivista
- DIGESTIVE AND LIVER DISEASE101
- GASTROENTEROLOGY100
- BLOOD89
- ANNALS OF ONCOLOGY78
- HAEMATOLOGICA56
- JOURNAL OF CLINICAL ONCOLOGY51
- NEUROLOGICAL SCIENCES46
- UNITED EUROPEAN GASTROENTEROLOGY ...46
- ANNALS OF THE RHEUMATIC DISEASES30
- REUMATISMO26
Keyword
- Helicobacter pylori10
- sclerosi sistemica6
- Bioengineering5
- Gastroenterology5
- HCV5
- UV5
- GERD4
- anodal stimulation3
- beat-to-beat variability of cardi...3
- capillaroscopia3
Lingua
- eng848
- ita160
- fre1
Accesso al fulltext
- no fulltext1625
- reserved26
- open6